DPx Holdings Acquires Gallus BioPharmaceuticals - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

DPx Holdings Acquires Gallus BioPharmaceuticals


DPx Holdings announced that it has reached a definitive agreement to acquire all shares of Gallus BioPharmaceuticals, LLC, a contract manufacturing company specializing in biologics.

Once the transaction is complete the two Gallus sites in St. Louis, Mo. and Princeton, N.J. will be the first Patheon biologic drug substance sites in the U.S. and will complement the two existing sites in Groningen, the Netherlands and Brisbane, Australia. Three of the four global sites each have nearly three decades of mammalian cell culture experience, while the fourth site in Brisbane was opened within the last year and is considered a facility of the future for biologics, the company reports.

DPx Holdings is the parent company of Patheon, DSM Fine Chemicals, and Banner Life Sciences. The Patheon pharma services business provides commercial manufacturing, pharmaceutical product development services for solid and sterile dosage forms, and biologic and chemical drug substance development and manufacturing. The addition of Gallus BioPharmaceuticals makes Patheon a provider of process development, as well as clinical and commercial scale manufacturing of mammalian cell culture-derived products. Patheon will offer its customers an array of disposable manufacturing technology, as well as commercial scale production.

Subject to receipt of regulatory approvals, the transaction is expected to close in the fourth quarter of 2014.

Source: DPx Holdings

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here